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(FLUOX-PMS): study protocol for a randomized
controlled trial
Melissa Cambron1*, Jop Mostert2, Patrick Haentjens3, Marie D’Hooghe4, Guy Nagels4, Barbara Willekens5,
Dorothea Heersema6, Jan Debruyne7, Wim Van Hecke8, Luc Algoed9, Nina De Klippel10, Erwin Fosselle11,
Guy Laureys1,12, Henri Merckx13, Bart Van Wijmeersch14, Ludo Vanopdenbosch15, Wim Verhagen16,
Raymond Hupperts17, Gerald Hengstman18, Veronique Michiels1, Annick Van Merhaegen-Wieleman1
and Jacques De Keyser1,6Abstract
Background: Currently available disease-modifying treatments acting by modifying the immune response are
ineffective in progressive multiple sclerosis (MS), which is caused by a widespread axonal degeneration. Mechanisms
suspected to be involved in this widespread axonal degeneration are reduced axonal energy metabolism, axonal
glutamate toxicity, and reduced cerebral blood flow. Fluoxetine might theoretically reduce axonal degeneration in
MS because it stimulates energy metabolism through enhancing glycogenolysis, stimulates the production of
brain-derived neurotrophic factor, and dilates cerebral arterioles. The current document presents the protocol of a
clinical trial to test the hypothesis that fluoxetine slows down the progressive phase of MS.
Methods/Design: The FLUOX-PMS trial is a multi-center, randomized, controlled and double-blind clinical study. A
total of 120 patients with the diagnosis of either secondary or primary progressive MS will be treated either by
fluoxetine (40 mg daily) or placebo for a total period of 108 weeks. The primary endpoint is the time to confirmed
disease progression defined as either at least a 20% increase in the timed 25-Foot Walk or at least a 20% increase in
the 9-Hole Peg Test. Secondary endpoints include the Hauser ambulation index, cognitive changes, fatigue,
magnetic resonance imaging of the brain, and in a small subgroup optical coherence tomography.
Discussion: The FLUOX-PMS trial will gives us information as to whether fluoxetine has neuroprotective effects in
patients with progressive MS.
Trial Registration: Eudra-CT: 2011-003775-11
Keywords: Multiple sclerosis, Primary progressive, Secondary progressive, Clinical trial, Fluoxetine, NeuroprotectionBackground
Multiple sclerosis (MS) is a chronic inflammatory and de-
generative disease and is considered the most important
non-traumatic cause of neurological disability in young
adults. Despite many decades of intensive research, the
cause of MS has remained elusive, and many aspects of
the pathogenesis are not understood. The disease appears* Correspondence: melissa.cambron@gmail.com
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reproduction in any medium, provided the orto precipitate in genetically susceptible individuals, very
likely as a result of an environmental trigger. An in-
fectious component has long been suspected, but no
specific transmissible agent has so far been linked
convincingly to MS [1].
The disease course of MS is heterogeneous. A major-
ity of patients initially has bouts of neurological deficit
(relapses) followed by (partial) recovery (the so-called
‘relapsing remitting’ stage). This stage is often followed
by a slowly progressive increase in disability (the stage
of ‘secondary progression’). Other patients develop pro-
gressive increase in neurological disability from onset,al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gressive form’) [1].
Focal inflammatory demyelinating lesions that develop
in eloquent areas within the CNS cause relapses. The pro-
gressive phase of MS, either secondary or primary, reflects
a poorly understood insidious widespread axonal degener-
ation that is age-related and independent of relapses [2-4].
Currently available disease-modifying treatments, which
act by modifying the inflammatory response, reduce the
frequency of relapses, but are not effective in progressive
MS [5-7].
Astrocytes in MS appear to be deficient in ß2 adrenergic
receptors [8], which activate a Gs protein that associates
with adenylate cyclase, leading to the conversion of ATP to
cAMP, which in turn activates protein kinase A (PKA).
Norepinephrine, via the stimulation of ß2 adrenergic recep-
tors, tightly suppresses the expression of interferon γ-
induced MHC class II molecules on cultured astrocytes [9].
We have proposed that downregulation of ß2 adrenergic re-
ceptors on astrocytes in MS may alter the phenotype of
astrocytes into facultative immunocompetent antigen pre-
senting cells that can initiate the inflammatory reactions
leading to demyelination [10,11]. Fluoxetine activates PKA
in astrocytes [12], and might thus compensate for the as-
trocytic ß2 adrenergic receptor deficiency. Based on this
hypothesis we performed a pilot study in patients with re-
lapsing remitting MS and found that a daily dose of 20 mg
tended to reduce the formation of new inflammatory lesions
on magnetic resonance imaging (MRI) of the brain [13].
Mechanisms proposed to be involved in the progressive
axonal degeneration in MS are reduced axonal energy me-
tabolism, axonal glutamate toxicity, and reduced cerebral
blood flow [14-16]. This might also be mediated by astro-
cytic dysfunction, associated with reduced astrocytic ß2
adrenergic receptors [11]. Fluoxetine might reduce pro-
gressive axonal loss in MS, through activation of PKA, as
it stimulates astrocytic glycogenolysis necessary for main-
tenance of sodium-dependent glutamate uptake by astro-
cytes, and the release of lactate, which serves as energy
source for axons [17,18]. Fluoxetine also stimulates the re-
lease of the neuroprotective brain-derived neurotrophic
factor (BDNF) from astrocytes [18], and may improve
cerebral blood flow by dilating cerebral arterioles inde-
pendent of the endothelium [19].
Two weeks of treatment with fluoxetine (first week
20 mg/day and second week 40 mg/day) significantly
improved cerebral white matter N-acetylaspartate/cre-
atine ratio in MS patients, suggesting an improvement
in axonal mitochondrial energy metabolism, because
N-acetylaspartate is produced by mitochondria [20].
Based on these preliminary findings we decided to
perform a randomized placebo-controlled trial to assess
whether fluoxetine has a neuroprotective effect in patients
with progressive MS.Secondary and primary progressive MS have a different
form of symptom onset but the underlying pathophysio-
logical mechanism leading to progressive axonal degener-
ation is likely the same. It is independent of relapses, and
the progressive phases of each proceed at remarkably
similar rates [1]. In addition the difference between the
progressive types is not always clear cut and often arbi-
trary as subjects with primary progressive MS can also
experience relapses.
Methods/Design
Trial design
FLUOX-PMS (FLUOXetine in Progressive Multiple Scler-
osis) is a multi-center, randomized, controlled parallel
group, and double-blind clinical trial conducted at dif-
ferent sites located in the Flemish region of Belgium, and
in The Netherlands. Recruitment in Belgium and The
Netherlands started in February 2012 and April 2013, re-
spectively. In total, 120 patients with either secondary or
progressive MS will be randomized to receive either two
tablets of fluoxetine 20 mg or placebo of identical appear-
ance, daily for 108 weeks. The study is approved by the
local ethics committees (See Additional file 1) and at the
national level by ‘Federaal Agentschap voor Geneesmiddelen
en Gezondheidsproducten’ (Belgium) and the ‘Centrale
Commissie Mensgebonden Onderzoek’ (Netherlands). The
study is registered at the European Union Drug Regulating
Authorities (Eudra-CT: 2011-003775-11). The study will be
conducted in accordance to the Declaration of Helsinki in
its currently applicable version, the guidelines of the Inter-
national Conference on Harmonization of Good Clinical
Practice (ICH-GCP), and the applicable Belgian and Dutch
legislation. All participants are required to give written in-
formed consent.
Participants
Inclusion criteria for participation in the FLUOX-PMS
trial comprise the diagnosis of either secondary or primary
progressive MS according to the revised 2010 McDonald
criteria [21], aged 25 to 65 years, a score between 3 and
6.5 included on the Expanded Disability Status Scale
(EDSS) [22], and documented confirmed evidence of dis-
ease progression independent of clinical relapses over the
1 year prior to enrolment, defined as an increase of 0.5
point on the EDSS. For sexually active female patients with
reproductive potential, use of reliable means of contracep-
tion is required. The main exclusion criteria include use of
antidepressants. Concomitant medications that may lead
to clinically significant interactions with fluoxetine (such
as monoamine oxidase inhibitors that could lead to a sero-
tonin syndrome) are not allowed. Other exclusion criteria
are pregnancy or lactation, other neurologic, serious psy-
chiatric (for example, major depression) or systemic dis-
orders that may interfere with the assessments. Use of
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allowed, except for interferon beta or glatiramer acet-
ate, as it has been shown that these drugs are ineffective
in slowing down progression [5-7]. Patients using other
immunosuppressive or immunomodulatory drugs can
only be included if stopped at least for 2 months before
randomization.
Study mediation, randomization, and follow-up
Eligibility of patients is determined at the screening visit
(week −4). At baseline visit, patients who qualify for partici-
pation in the study are randomized 1:1 using a block size
of 10, to receive either fluoxetine or placebo. Study medica-
tion (verum and placebo) was purchased from Eurogene-
rics and stored at the department of Pharmacy of the UZ
Brussel. After inclusion, patients are given a computer-
generated randomization number, which is matched to a
confidential treatment number by the study pharmacist of
the UZ Brussel to assign patients either to fluoxetine or to
placebo.
Trained study nurses visit patients at home to perform
all assessments in their natural environment, avoiding the
stress and efforts of going to the hospital, which may
interfere with clinical assessments. They plan the brain
MRI scans, provide the study medication, and will be con-
tacted in case of adverse events, suspected relapse, or
questions. Counting tablet returns at each visit will assess
adherence. In case of a suspected relapse they will refer
the patient to their treating neurologist. All patients are
followed as usually by their treating neurologist. When
there is a change in immunomodulatory treatment or anti-
depressants have to be started, the treating neurologist is
kindly asked to notify the study team.
Regular study visits are carried out at weeks 0, 12, 24,
36, 48, 60, 72, 84, 96, and 108. An optional follow-up
visit will be offered at week 120 to confirm sustained
progression appearing at week 108. If necessary, add-
itional unscheduled visits can be performed at any time.
The study flow-chart is shown in Figure 1.
Primary outcome parameter
The primary endpoint is the time to confirmed disease
progression defined as either at least a 20% increase in
the timed 25-Foot Walk (T25-FW) or at least a 20% in-
crease in the 9-Hole Peg Test (9-HPT; assessment of
upper limb function). In each situation the change can-
not be attributed to another etiology (for example, fever,
concurrent illness, relapse), and is sustained for at
least ≥12 weeks up to the end of the trial.
In the T25-FW the patient is directed to one end of a
clearly marked 25-foot course and is instructed to walk
25 feet (7.26 m) as quickly as possible, but safely. The
time is calculated from the instruction to start and ends
when the patient has reached the 25-foot mark. The taskis immediately administered again by having the patient
walk back the same distance. The score for the T25-FW
is the average of the two completed trials. Patients may
use assistive devices when doing this task. Because mo-
bility may be affected by factors such as spasticity and
the use of different walking aids, subsequent tests be-
tween weeks 12 and 120 will be performed with the
same walking aid if any, and on the same dose of anti-
spasticity medication if any.
In the 9-HPT, the patient is seated at a table with a
small, shallow container holding nine pegs and a wood or
plastic block containing nine empty holes. On a start com-
mand when a stopwatch is started, the patient picks up
the nine pegs one at a time as quickly as possible, puts
them in the nine holes, and, once they are in the holes,
removes them again as quickly as possible one at a time,
replacing them into the shallow container. The total time
to complete the task is recorded. Two consecutive trials
with the dominant hand are immediately followed by two
consecutive trials with the non-dominant hand. The over-
all 9-HPT score is the average of the four trials.Secondary outcome parameters
The following secondary clinical endpoints will be assessed:
(1) the proportion of patients without sustained 20% in-
crease in the T25-FW, or without 20% increase in the 9-
HPT between weeks 12 and 108; (2) the proportion of
patients with a stable Hauser ambulation index; (3) cog-
nitive changes measured through a cognitive battery;
and (4) fatigue.
The Hauser ambulation index is a rating scale to assess
mobility by evaluating the time and degree of assistance
required to walk 25 feet. Scores range from 0 (asymp-
tomatic and fully active) to 10 (bedridden). The patient is
asked to walk a marked 25-foot course as quickly and
safely as possible. The examiner records the time and type
of assistance (for example, cane, walker, crutches) needed.
The cognitive battery consists of the Symbol Digit Mo-
dalities Test (SDMT), California Verbal Learning Test–II
(CVLT-II), and Controlled Oral Word Association Test
(COWAT). The Beck depression inventory-II (BDI-II) will
be used to get a view on the depression level of the patient.
Fatigue will be assessed with the Modified fatigue Im-
pact Scale (MFIS).
Secondary surrogate endpoints comprise brain magnetic
resonance imaging (MRI) data, and in some selected cen-
ters changes in the retinal nerve fiber layer thickness and
macular volume between weeks 12 and 108 will be mea-
sured using optical coherence tomography (OCT).MRI of the brain
MRI analyses will be performed in five hospitals on a 3
tesla MRI scanner (Philips and Siemens). During each
Figure 1 Trial flow chart (see also list of abbreviations).
Cambron et al. Trials 2014, 15:37 Page 4 of 7
http://www.trialsjournal.com/content/15/1/37scan session, the following sequences are acquired: 3D
T1 (TE, 2.93 ms; TR, 2,300 ms; TI, 900 ms; voxel size,
1.1 × 1.1 × 1.2 mm3; acquisition time, 5.12 min), 3D T2(TE, 402 ms; TR, 3,200 ms; voxel size, 1 × 1 × 1 mm3;
acquisition time, 4.43 min), 3D FLAIR (TE, 388 ms; TR,
5,000 ms; TI, 1,800 ms; voxel size, 1 × 1 × 1 mm3;
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tions, b, 800 s/mm2; TE, 85 ms; TR, 8,500 ms; voxel
size, 2 × 2 × 2 mm3; acquisition time, 9.48 min). Each
subject will undergo two scans (at weeks 12 and 108) at
the same hospital to guarantee that both scans are
made under identical conditions. An automated soft-
ware algorithm will be used to detect focal MS lesions.
This performs an intensity-based tissue classification
using a stochastic model for normal brain images and
detects MS lesions as outliers that are not well ex-
plained by the model. The T1, T2, and FLAIR images
will be used as input for the lesion segmentation soft-
ware. Reduction in brain parenchymal fraction (BPF) is
used as a normalized measure of whole-brain atrophy.
BPF is measured from the 3D T1-weighted images from
each time point using a fully automated method. Diffu-
sion tensor MRI (quantified by fractional anisotropy
and apparent diffusion coefficient) will be used to as-
sess white matter tissue integrity. To this end, all DTI
datasets will be aligned to a population-specific atlas.
Subsequently, diffusion parameters will be evaluated
statistically in every white matter voxel. All MRI pa-
rameters will be gathered and assessed by an experi-
enced evaluator (ICOMETRIX) who is blinded to both
clinical data and treatment allocation. Because it is a
secondary outcome parameter, brain MRI is not com-
pulsory for patients having difficulty to undergo this
examination.
Sample size
The sample size was estimated on the basis of a study in
untreated patients with primary progressive multiple scler-
osis [23]. The primary event is sustained worsening on the
T25-FW or 9-HPT within 2 years using a survival analysis.
At 2 years the fraction of event-free patients is estimated
to be 45% in the untreated group, and 70% in the
fluoxetine-treated group. Using sample size calculation for
comparing two survival curves (StatemateTM, GraphPad
software, San Diego, CA, USA), including 60 patients in
each group has 80% power to detect an increase in sur-
vival proportion of 0.25 with a significance level (alpha) of
0.05 (two-tailed). For every patient who drops out within
the first 3 months, which is the period when we expect
most drop-outs, a new patient will be included until a
sample size of 120 patients is reached.
Blinding and statistical methods
Patients and the entire study staff will remain blinded
throughout the complete treatment period. Treatment
allocations will only be disclosed after the final database
lock. Independent examiners will do MRI and OCT
evaluations. All data will be statistically analyzed by an
independent biometrician. Proportion of patients will be
analyzed with the use of a chi-square test. A log-ranktest will be applied to compare differences in time to
confirmed disease progression between the two treat-
ment groups. A Cox proportional hazard model will be
used to estimate the reduction in hazard associated with
treatment compared with placebo. Repeated measures
analysis of covariance will be used to compare differ-
ences between the fluoxetine and placebo group in end-
points related to changes from baseline. The test level
for statistical significance of differences between both
treatment arms is defined as P = 0.05 for all tests.
Discussion
So far, no drug has been able to slow down progressive
MS. Fluoxetine is mainly indicated for the treatment of
mild-to-moderate depression, but the drug has potential
pleiotropic neuroprotective effects [24]. The patent of flu-
oxetine expired in 2001. Because it is an old drug its side-
effect profile, which is in general mild, is well established.
Some aspects of the trial need clarification. First, because
it may take several weeks before a steady state of fluoxet-
ine level in blood and brain is achieved [25], progression is
measured from the second visit at 12 weeks, and not from
start of the trial. Second, the choice of the dose of fluoxet-
ine 40 mg is based on clinical practice indicating that dos-
ages of 20 to 40 mg are effective in neuropsychiatric
disorders. Third, the trial lasts for 2 years, because observ-
ing progression for 2 years is more meaningful than for 1
year [23]. Fourth, we decided not to use the EDSS as pri-
mary outcome measure because study nurses assess the
patients in our study and the EDSS is a rather insensitive
measure to assess progression. Fifth, we use cutoffs of 20%
for both T25-FW and 9-HPT, because this has a better
signal-to-noise ratio than lower values (for example, 15%)
and is therefore preferable for the assessment of disease
progression [26]. In a group of 161 primary progressive
multiple sclerosis patients, Bosma and colleagues found
that progression as measured with the objective outcome
measures T25-FW or 9-HPT was 56% at 2 years. Combin-
ing T25-FW or 9-HPT or EDSS resulted in a slightly
higher event rate of 63%. Sixth, we do not exclude patients
on first-line immunomodulatory drugs (interferons and
glatiramer acetate) since they have shown in clinical trials
to be inefficacious in progressive MS. From a methodo-
logical point of view, a design without immunomodulatory
drugs would be preferable. Because many neurologists use
these drugs off-label in progressive MS we feel that exclud-
ing these patients would seriously hamper patient recruit-
ment. The main reason for exclusion during the screening
phase is the use of antidepressants, which is frequently in-
dicated in progressive MS patients.
Our trial has a unique design, which, to the best of
our knowledge, has not been used before. Traditionally,
MS patients participating to a clinical trial are assessed
on a regular basis by neurologists and study nurses at
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patients at their home. This avoids stress and physical ef-
fort associated with attending the hospital, and ensures
that all functional tests are done in the patient’s natural
environment.
Trial status
The FLUOX-PMS trial is currently recruiting patients.
Additional file
Additional file 1: Description of data: List of ethical committees of
recruiting centers.
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